RecruitingNot Applicable

EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions Registry

United States50 participantsStarted 2026-03-10

Plain-language summary

This is a single-center, investigator-initiated, prospective observational registry that will collect longitudinal clinical data on adult patients (≥18 years) undergoing endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) or microwave ablation (MWA) for pancreatic and other gastrointestinal/hepatobiliary lesions as part of routine clinical care. The registry will not alter standard-of-care management. Data will be abstracted from the medical record and routine clinical systems. Primary outcomes include change in target lesion size on clinically obtained imaging and overall survival following ablation. Secondary outcomes include changes in tumor biomarkers, adverse events, non-target lesion changes, and patient-reported symptoms.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults ≥ 18 years of age. * Diagnosis of a pancreatic premalignant lesion or malignancy, and other gastrointestinal or hepatobiliary lesion for which EUS-guided ablation is planned as part of standard clinical care. * At least one clinically identified target lesion for which RFA or MWA is performed. Exclusion Criteria: * In the judgment of the treating clinician, inclusion in the registry would not be appropriate * The individual is expected to be unable to complete routine clinical follow-up.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change From Baseline to 1 Month in Target Lesion Size

Timeframe: Baseline to 1 month

Change From Baseline to 3 Months in Target Lesion Size

Timeframe: Baseline to 3 months

Change From Baseline to 6 Months in Target Lesion Size

Timeframe: Baseline to 6 months

Change From Baseline to 12 Months in Target Lesion Size

Timeframe: Baseline to 12 months

Overall Survival

Timeframe: From ablation to death or last follow-up, assessed up to 1 year

Overall Survival

Timeframe: From ablation to death or last follow-up, assessed up to 3 year

Trial details

NCT IDNCT07625189

SponsorWest Virginia University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-03

Contact for this trial

Zim Warda Hasan

364-203-1900 zh00027@mix.wvu.edu

View on ClinicalTrials.gov More RFA trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change From Baseline to 1 Month in Target Lesion Size

Timeframe: Baseline to 1 month

Change From Baseline to 3 Months in Target Lesion Size

Timeframe: Baseline to 3 months

Change From Baseline to 6 Months in Target Lesion Size

Timeframe: Baseline to 6 months

Change From Baseline to 12 Months in Target Lesion Size

Timeframe: Baseline to 12 months

Overall Survival

Timeframe: From ablation to death or last follow-up, assessed up to 1 year

Overall Survival

Timeframe: From ablation to death or last follow-up, assessed up to 3 year